£810 / $1295 / €985
The revival of the THB30 healthcare scheme in September 2012 will do little to ease the financial burden the government is facing as a result of the universal healthcare scheme. Nor will it solve existing issues such as the shortage of medical professionals and hospital overcrowding, given that these problems existed when the scheme was first implemented. We highlight that universal healthcare coverage will prove to be financially unsustainable in the long term, due to various factors - including Thailand's ageing population (and therefore increased burden of non-communicable diseases), medical tourism and the creation of the region-wide ASEAN Economic Community 2015 that is leading to the exit of medical professionals from Thailand 's public health sector.
Headline Expenditure Projections
Pharmaceuticals: THB130.95bn (US$4.41bn) in 2011 to THB136.34bn (US$4.18bn) in 2012; +4.1% in local currency terms and -5.1% in US dollar terms. Forecast broadly unchanged from Q4 12.
Healthcare: THB405.84bn (US$13.31bn) in 2011 to THB429.15bn (US$13.16bn) in 2012; +5.7% in local currency terms and -1.1% in US dollar terms. Forecast broadly unchanged from Q4 12.
Medical devices: THB33.88bn (US$1.11bn) in 2011 to THB39.09bn (US$1.20bn) in 2012; +15.4% in local currency terms and 7.9% in US dollar terms. Forecast broadly unchanged from Q4 12.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.